Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of VH4527079 in Healthy Adults and Persons With HIV
NCT06652958Phase 1Terminated
- Sponsor
- ViiV Healthcare
- Start
- Oct 2024
- Primary completion
- Sep 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of VH4527079 in human immunodeficiency virus infection (HIV) (9 cohorts), sponsored by ViiV Healthcare. Primary endpoints: Number of participants with adverse events (AEs) of Grade 2 and above severity, Area under the plasma-concentration time curve from time zero to infinity and 5 more. Started Oct 2024; status: terminated.
02
Drugs
VH4527079
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06652958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06652958.